CSG at a Crossroads: Shareholder Feud, Production Doubts, and a Pivotal Q1 Report Loom Over Recovery

Czechoslovak Group enters maiden earnings with stock down 53% amid shareholder dispute, production credibility doubts, and Slovak munitions regulatory delays, despite record revenue.

The Czechoslovak Group enters its maiden quarterly earnings season on 20 May carrying an unusually heavy load. Three distinct crises — a €1.4 billion shareholder claim, a short-seller attack on production credibility, and a regulatory hitch in Slovakia's munitions framework — have conspired to drag the stock 53% below its January peak, even as the underlying business posts record numbers.

The Kratochvíl Put-Option Dispute

Days before the IPO, minority shareholder Petr Kratochvíl is said to have exercised a put option demanding €1.4 billion for his 10% stake in CSG Land Systems. That entity controls roughly two-thirds of the group's 2024 revenue and held €578 million in cash at the time. Kratochvíl also retains blocking rights over key decisions at the unit.

CSG firmly disputes the validity of the exercise. External legal counsel has advised that the option was not effectively executed before the listing, and therefore no actual or contingent liability exists that would require disclosure in the audited accounts. The company attributes the removal of a related passage from its annual report to a software error — a explanation Seznam Zprávy questioned. The Dutch financial watchdog AFM has declined to comment on whether it is investigating potential misleading statements.

Hunterbrook Casts Doubt on Munitions Output

A separate storm has gathered around CSG's core production narrative. The short-seller Hunterbrook Media challenges the company's publicly stated annual capacity of roughly 630,000 155mm artillery shells, estimating actual output from the main production line at just 100,000 to 280,000 units last year. If a significant portion of munitions revenue comes from re-selling third-party stock rather than in-house manufacturing, the margins and growth story underpinning the IPO would be substantially weaker.

CSG has rejected the allegations outright, pointing to the due diligence conducted before the listing. The company confirms a 20% increase in own production for 2026, including a new line in Slovakia adding 70,000 units. Its medium-term target stands at 1.1 million rounds, spread across facilities in Slovakia, Greece, Serbia, Spain, and India.

Regulatory and Political Headwinds

Beyond the courtroom and the analyst note, operational friction is building. A NATO procurement agency temporarily suspended a Spanish munitions factory owned by CSG over alleged sanctionable practices — a charge the group denies. Meanwhile, Slovakia's ambition to secure favourable EU financing under the SAFE programme for its munitions framework requires at least one other member state to participate. Romania's ministry has ruled out involvement, Croatia is still evaluating, and Poland and Greece have remained non-committal. The exemption allowing single-state participation expires at the end of May 2026.

Record Operations, Shrinking Share Price

Despite these pressures, the group's financials tell a starkly different story. Revenue surged 71.7% last year to €6.74 billion, adjusted EBIT hit €1.6 billion, and net profit reached €872 million. The EBIT margin came in at 24.1%. The order backlog stood at €15 billion, with a pipeline of €27 billion — together forming a combined order book of €42 billion.

For 2026, management guides for revenue of €7.4–€7.6 billion and an adjusted EBIT margin of 24–25%. Moody’s upgraded CSG in February from Ba1 to Baa3, while Fitch held at BBB- with a stable outlook. A €275 million receivable from the disposal of non-core businesses — CSG Mobility, Perazzi, and Healthcare — was settled in the first quarter.

Investor sentiment, however, has decoupled from fundamentals. The stock closed Tuesday at €16.01, barely above the 52-week low of €15.73. The monthly decline reached 29%, and the 30-day annualised volatility stands at 77.66%. Analysts remain bullish: all nine covering the stock rate it a buy, with a median target of €35.40 — more than double the current price.

The 20 May Verdict

The first-quarter report will be the group's debut as a listed entity and the first hard data point to test both its operational narrative and its handling of the outstanding disputes. The market's faith is fragile. For CSG, the numbers on 20 May will either validate the record order books or deepen the crisis of confidence.